Eli Lilly CDR (CAD Hedged)
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: LY2189265
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT01408888
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Bioavailability Study of LY2452473 and Tadalafil
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01401543
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4299
- Registration Number
- NCT01400971
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, United Kingdom
A Relative Bioavailability and Food Effect Study of New Formulations
- Conditions
- Chronic Inflammatory DisorderArthritis, Rheumatoid
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT01398475
- Locations
- πΈπ¬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
- Conditions
- Cardiovascular DiseaseDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9901
- Registration Number
- NCT01394952
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Londonderry, United Kingdom
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 225
- Registration Number
- NCT01394016
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States
πΊπΈFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States
A Study of LY2584702 in Participants With Advanced Cancer
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT01394003
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Study of LY2228820 in Participants With Advanced Cancer
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 89
- Registration Number
- NCT01393990
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 110
- Registration Number
- NCT01391130
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 22
- Registration Number
- NCT01389752
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States